Table 2.

Brain regions showing dose-related effects of ondansetron

	BA	k	x	y	z	pcorr	r	r lower	r upper
Insula (middle, posterior) (L)	13	1409	−38	−10	4	0.02	0.57	0.35	0.73
Superior temporal (L)	22, 41, 42		−38	−36	8	0.04
Precentral/inferior frontal/postcentral (L)	2, 6, 9, 43, 44		−54	6	26	0.03
Insula (middle, posterior) (R)	13	1165	36	−36	10	0.02	0.55	0.33	0.71
Superior/middle temporal (R)	22, 38, 41, 42		60	−16	10	0.03
Postcentral/precentral (R)	2, 3, 4, 6	595	58	−8	36	0.03	0.56	0.33	0.71
Anterior cingulate (B)	33	158	−6	6	30	0.04	0.52	0.29	0.69
Middle frontal (L)	9	36	−36	36	32	0.05	0.46	0.22	0.65
Supplementary motor area (R)	6	19	12	2	58	0.05	0.51	0.27	0.68
Supplementary motor area (L)	6	17	−6	2	48	0.05	0.44	0.19	0.63
Insula (posterior)/superior temporal	13	16	−46	−36	18	0.05	0.44	0.19	0.63

Data are whole-brain corrected at a family-wise error rate of p < 0.05 using threshold-free cluster enhancement and nonparametric permutation analysis. Positive correlation coefficients reflect greater reductions (i.e., decreased activity) for OND (compared to PL) as dosage increases

BA Brodmann’s areas, k cluster extent, pcorr whole-brain-corrected p value, R right, L left, B bilateral, r Pearson’s correlation coefficient with 95% confidence interval bounds, coordinates are in MNI space